2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

chimeric monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

5

Peptides

25

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99628
    Futuximab

    		EGFR Cancer
    Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .
    Futuximab
  • HY-P99362
    Ensituximab

    Anti-MUC5AC Reference antibody (ensituximab); NEO-102

    		 Mucin Cancer
    Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .
    Ensituximab
  • HY-P9913
    Rituximab
    5+ Cited Publications

    Anti-Human CD20 type I, chimeric antibody

    		 Radionuclide-Drug Conjugates (RDCs) CD20 Inflammation/Immunology Cancer
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
    Rituximab
  • HY-P9913A
    Rituximab (anti-CD20)
    5+ Cited Publications

    		 CD20 Inflammation/Immunology Cancer
    Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
    Rituximab (anti-CD20)
  • HY-P99686
    Larcaviximab

    c4G7-N

    		 Filovirus Infection
    Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody .
    Larcaviximab
  • HY-P3149B
    LEESGGGLVQPGGSMK acetate

    		TNF Receptor Inflammation/Immunology
    LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
    LEESGGGLVQPGGSMK acetate
  • HY-108852
    Basiliximab

    CHI 621

    		 Interleukin Related Inflammation/Immunology Cancer
    Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
    Basiliximab
  • HY-P3203A
    DSTYSLSSTLTLSK TFA

    		TNF Receptor Inflammation/Immunology
    DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
    DSTYSLSSTLTLSK TFA
  • HY-P3203
    DSTYSLSSTLTLSK

    		Biochemical Assay Reagents Inflammation/Immunology
    DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
    DSTYSLSSTLTLSK
  • HY-P3149
    LEESGGGLVQPGGSMK

    		TNF Receptor Inflammation/Immunology
    LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
    LEESGGGLVQPGGSMK
  • HY-P99023
    Girentuximab
    1 Publications Verification

    G250; cG250

    		 Carbonic Anhydrase Cancer
    Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
    Girentuximab
  • HY-P3149A
    LEESGGGLVQPGGSMK TFA

    		TNF Receptor Inflammation/Immunology
    LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
    LEESGGGLVQPGGSMK TFA
  • HY-P990084
    Veligrotug

    		IGF-1R Cancer
    Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody .
    Veligrotug
  • HY-P99832
    Cosfroviximab

    c13C6-FR1

    		 Filovirus Infection
    Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP) .
    Cosfroviximab
  • HY-P99607
    Clenoliximab

    IDEC-151

    		 HIV Inflammation/Immunology
    Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
    Clenoliximab
  • HY-P99105
    Anselamimab

    CAEL-101

    		 Apolipoprotein Amyloid-β Neurological Disease
    Anselamimab (CAEL-101) is a chimeric monoclonal antibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis .
    Anselamimab
  • HY-P99538
    Ublituximab

    LFB-R603; TG-1101; TGTX-1101

    		 CD20 Cancer
    Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
    Ublituximab
  • HY-P99030
    Margetuximab

    		EGFR Cancer
    Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
    Margetuximab
  • HY-P9934
    Abciximab
    1 Publications Verification

    C7E3

    		 Integrin Cardiovascular Disease
    Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
    Abciximab
  • HY-P99530
    Valanafusp alfa

    AGT-181; HIRMAb-IDUA

    		 Insulin Receptor Metabolic Disease
    Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
    Valanafusp alfa
  • HY-P991141
    Inlecitug

    		VEGFR Cancer
    Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
    Inlecitug
  • HY-P9970
    Infliximab
    Maximum Cited Publications
    14 Publications Verification

    Avakine; CT-P13

    		 TNF Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
    Infliximab
  • HY-P99351
    Andecaliximab

    Anti-MMP9 Reference antibody (andecaliximab)

    		 MMP Cancer
    Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
    Andecaliximab
  • HY-P99321
    Teneliximab

    BMS 224819; Chi220; Anti-Human CD40 Recombinant antibody

    		 TNF Receptor Inflammation/Immunology Cancer
    Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
    Teneliximab
  • HY-P991113
    Abazistobart

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
    Abazistobart
  • HY-P99680
    Keliximab

    SB-210396; IDEC CE9.1

    		 Interleukin Related Cancer
    Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
    Keliximab
  • HY-P9933
    Dinutuximab

    APN-311

    		 Apoptosis PERK mTOR Cancer
    Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer .
    Dinutuximab
  • HY-P9970A
    Infliximab (Anti-TNF-α)

    Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)

    		 TNF Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
    Infliximab (Anti-TNF-α)
  • HY-P99008
    Atibuclimab
    1 Publications Verification

    IC14

    		 Toll-like Receptor (TLR) Infection Neurological Disease Inflammation/Immunology
    Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
    Atibuclimab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: